Australia markets closed
  • ALL ORDS

    7,577.20
    +18.40 (+0.24%)
     
  • ASX 200

    7,312.30
    +9.80 (+0.13%)
     
  • AUD/USD

    0.7708
    -0.0002 (-0.02%)
     
  • OIL

    71.59
    +0.68 (+0.96%)
     
  • GOLD

    1,857.90
    -21.70 (-1.15%)
     
  • BTC-AUD

    51,299.37
    +5,156.58 (+11.18%)
     
  • CMC Crypto 200

    985.04
    +43.23 (+4.59%)
     
  • AUD/EUR

    0.6363
    -0.0000 (-0.00%)
     
  • AUD/NZD

    1.0802
    -0.0006 (-0.06%)
     
  • NZX 50

    12,562.17
    +11.78 (+0.09%)
     
  • NASDAQ

    13,998.30
    +38.00 (+0.27%)
     
  • FTSE

    7,153.17
    +19.11 (+0.27%)
     
  • Dow Jones

    34,479.60
    +13.40 (+0.04%)
     
  • DAX

    15,733.91
    +40.64 (+0.26%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • NIKKEI 225

    29,161.80
    +213.07 (+0.74%)
     

Insights on the Oligonucleotide Therapeutics Global Market to 2027 - Featuring Arrowhead Pharmaceuticals, GlaxoSmithKline and Ionis Pharmaceuticals Among Others - ResearchAndMarkets.com

·2-min read

The "Oligonucleotide Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Oligonucleotide Therapeutics estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027.

Neurological Disorders, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cancer segment is readjusted to a revised 11.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $426.2 Million, While China is Forecast to Grow at 7.6% CAGR

The Oligonucleotide Therapeutics market in the U.S. is estimated at US$426.2 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$434.4 Million by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 6.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Other Applications Segment to Record 6.1% CAGR

In the global Other Applications segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$97.7 Million in the year 2020 will reach a projected size of US$148.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$288.6 Million by the year 2027.

Select Competitors (Total 44 Featured):

  • Arrowhead Pharmaceuticals, Inc.

  • GlaxoSmithKline PLC

  • Ionis Pharmaceuticals, Inc.

  • miRagen Therapeutics, Inc.

  • Sarepta Therapeutics Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 44

For more information about this report visit https://www.researchandmarkets.com/r/ej4nzj

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005543/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900